# Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion

> **NCT02429726** · PHASE2 · UNKNOWN · sponsor: **Shenzhen SiBiono GeneTech Co.,Ltd** · enrollment: 90 (estimated)

## Conditions studied

- Malignant Pleural Effusion

## Interventions

- **DRUG:** rAdp53
- **DRUG:** Cisplatin
- **DRUG:** rAdp53 plus cisplatin

## Key facts

- **NCT ID:** NCT02429726
- **Lead sponsor:** Shenzhen SiBiono GeneTech Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2015-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02429726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02429726, "Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02429726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*